在癌症治疗领域，辅助分子的功效仍然是临床研究关注的焦点，目的是降低毒性并获得更好的结果。导致肿瘤发展、肿瘤进展、衰老和毒性增加的大多数发病过程都涉及炎症。炎症机制可以通过多种分子模式进展。众所周知，衰老过程是由与导致癌症发展的病理途径非常相似且通常平行的病理途径决定的。在这些复杂的机制中，炎症目前得到了广泛的研究，并且在老年医学领域通常被称为“炎症”。在这种情况下，积极控制炎症机制的治疗可以起到标准疗法的辅助作用。在这些新兴分子中，水飞蓟宾已在不同肿瘤类型中证明了其抗炎特性，也与化疗药物联合使用。此外，这种分子可能代表着年龄相关过程管理的突破。因此，水飞蓟宾可能是一种有价值的佐剂，可减少药物相关毒性并增加治疗潜力。因此，本综述的主要目的是收集和分析文献中有关水飞蓟宾使用的数据，以更好地了解该分子的功能机制及其可能的治疗作用。

In the landscape of cancer treatments, the efficacy of coadjuvant molecules remains a focus of attention for clinical research with the aim of reducing toxicity and achieving better outcomes. Most of the pathogenetic processes causing tumour development, neoplastic progression, ageing, and increased toxicity involve inflammation. Inflammatory mechanisms can progress through a variety of molecular patterns. As is well known, the ageing process is determined by pathological pathways very similar and often parallel to those that cause cancer development. Among these complex mechanisms, inflammation is currently much studied and is often referred to in the geriatric field as 'inflammaging'. In this context, treatments active in the management of inflammatory mechanisms could play a role as adjuvants to standard therapies. Among these emerging molecules, Silibinin has demonstrated its anti-inflammatory properties in different neoplastic types, also in combination with chemotherapeutic agents. Moreover, this molecule could represent a breakthrough in the management of age-related processes. Thus, Silibinin could be a valuable adjuvant to reduce drug-related toxicity and increase therapeutic potential. For this reason, the main aim of this review is to collect and analyse data presented in the literature on the use of Silibinin, to better understand the mechanisms of the functioning of this molecule and its possible therapeutic role.